GSK scores promising data on flu vaccines; Intrexon extends big lab lease; Curis gains milestones;

Conversation on Twitter :

 @FierceBiotech: Pfizer wins popularity contest in social media survey of patients. Item | Follow @FierceBiotech

 @JohnCFierce: In case you missed it Friday, my analysis on Q3 venture numbers (good) and top 10 deals of the quarter. Special Report | Follow @JohnCFierce

 @RyanMFierce: Quintiles reels in pharma business with IT game changers. More | Follow @RyanMFierce

> GlaxoSmithKline ($GSK) says it had garnered positive data from 5 late-stage studies of two quadrivalent flu vaccines. Story

> Intrexon, the synthetic biology company, has signed on to extend its big, 55,000-square-foot lease of lab space in Germantown, MD. Release

> Late last week Curis reported that it had achieved the first two development milestones under its agreement with The Leukemia & Lymphoma Society for the development of CUDC-907, an oral small molecule drug candidate inhibitor of PI3K and histone deacetylase. Release

Pharma News

@FiercePharma: Merck is a champion donor, charity pub says. Ranks 2nd for corporate giving, as % of pretax profits.--Forbes. More | Follow @FiercePharma

> Pfizer snags new ADHD drug in $680M NextWave deal. Story

> Novartis balks at Eylea-vs.-Lucentis data. Article

> Turkey eyes a $23B pharma sector by 2023, up from $5B. News

> Generic savings tell a different patent-loss tale. Report

Medical Device News

 @FierceMedDev: Israel's growing medical device industry gains a public stage this week. More | Follow @FierceMedDev

 @MarkHFierce: W.L. Gore has the final piece in place for its REDUCE Clinical study, to test a new stroke prevention device. More | Follow @MarkHFierce

 @DamianFierce: WuXi AppTec is making a splash in biologics, launching a cGMP plant in China. More | Follow @DamianFierce

> Edwards wins broader FDA approval for Sapien heart valve. More

> Wright takes down knee website after Stryker suit. Story

CRO News

> Lundbeck seeks partners on Alzheimer's drug after EMA rejection. Item

> Korean group enlists WCCT to spur drug development. More

> WuXi launches China's first GMP-friendly biologics plant. News

> Catalent looks to bridge industry, academia on drug delivery. Article

Biotech IT News

> Quintiles reels in pharma business with IT game changers. Story

> Appistry grabs distribution of MIT-Harvard genome toolkit. Report

> Big Pharma consortium to share cancer trial data. Article

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.